GlassScriptPhysician profile
Maximiliano E Hernandez
NPI 1477525384
$16,990.67
in general payments reported to CMS, 2019-2025
33 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,983 · 2020: $2,645 · 2021: $2,774 · 2022: $2,019 · 2023: $2,500 · 2024: $1,891 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,431 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,431.49 |
| Education | $138.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,396.83 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $2,246.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,940.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,853.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,276.57 | 2019-2025 | |
| Abbvie INC. | $1,211.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,042.54 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $883.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $737.31 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $542.39 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $510.74 | 2019-2023 | Myrbetriq |
| Amarin Pharma, INC. | $355.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $354.25 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Allergan, INC. | $314.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.93 | 2019-2024 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $168.82 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $154.84 | 2019-2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $113.55 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $112.01 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $107.16 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $101.55 | 2023-2024 | Linzess |
| Medtronic, INC. | $101.40 | 2022 | |
| Lundbeck LLC | $46.37 | 2025 | Rexulti |
| Radius Health, INC. | $38.48 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $34.13 | 2025 | Gemtesa |
| Exact Sciences Corporation | $27.26 | 2024 | Cologuard Collection Kit |
| Corium, LLC | $23.42 | 2023 | Adlarity |
| Paratek Pharmaceuticals, INC. | $23.02 | 2025 | Nuzyra |
| Lexicon Pharmaceuticals, INC. | $21.89 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $21.52 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $20.82 | 2024 | Nexletol |
| Ucb, INC. | $14.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maximiliano Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.